Literature DB >> 19239377

Hospital-associated Clostridium difficile infection: is it necessary to track community-onset disease?

Erik R Dubberke1, Kathleen M McMullen, Jennie L Mayfield, Kimberly A Reske, Peter Georgantopoulos, David K Warren, Victoria J Fraser.   

Abstract

OBJECTIVES: To compare Clostridium difficile infection (CDI) rates determined with use of a traditional definition (ie, with healthcare-onset CDI defined as diagnosis of CDI more than 48 hours after hospital admission) with rates determined with use of expanded definitions, including both healthcare-onset CDI and community-onset CDI, diagnosed within 48 hours after hospital admission in patients who were hospitalized in the previous 30 or 60 days, and to determine whether differences exist between patients with CDI onset in the community and those with CDI onset in a healthcare setting.
DESIGN: Prospective cohort.
SETTING: Tertiary acute care facility. PATIENTS: General medicine patients who received a diagnosis of CDI during the period January 1, 2004, through December 31, 2005.
METHODS: CDI was classified as healthcare-onset CDI, healthcare facility-associated CDI after hospitalization within the previous 30 days, and/or healthcare facility-associated CDI after hospitalization within the previous 60 days. Patient demographic characteristics and medication exposures were obtained. The CDI incidence with use of each definition, CDI rate variability, patient demographic characteristics, and medication exposures were compared.
RESULTS: The healthcare-onset CDI rate (1.6 cases per 1,000 patient-days) was significantly lower than the 30-day healthcare facility-associated CDI rate (2.4 cases per 1,000 patient-days; P< .01) and the 60-day healthcare facility-associated CDI rate (2.6 cases per 1,000 patient-days; P< .01). There was good correlation between the healthcare-onset CDI rate and both the 30-day (correlation, 0.69; P< .01) and 60-day (correlation, 0.70; P< .01) healthcare facility-associated CDI rates. There were no months in which the CDI rate was more than 3 standard deviations from the mean. Compared with patients with healthcare-onset CDI, patients with community-onset CDI were less likely to have received a fourth-generation cephalosporin (P= .02) or intravenous vancomycin (P+ .01) during hospitalization.
CONCLUSIONS: Compared with the traditional definition, expanded definitions identify more patients with CDI. There is good correlation between traditional and expanded CDI definitions; therefore, it is unclear whether expanded surveillance is necessary to identify an abnormal change in CDI rates. Cases that met the expanded definitions were less likely to have occurred in patients with fourth-generation cephalosporin and vancomycin exposure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19239377      PMCID: PMC3598605          DOI: 10.1086/596604

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  13 in total

1.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

2.  Nosocomial acquisition of Clostridium difficile infection.

Authors:  L V McFarland; M E Mulligan; R Y Kwok; W E Stamm
Journal:  N Engl J Med       Date:  1989-01-26       Impact factor: 91.245

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital.

Authors:  M F Price; T Dao-Tran; K W Garey; G Graham; L O Gentry; L Dhungana; H L Dupont
Journal:  J Hosp Infect       Date:  2006-12-04       Impact factor: 3.926

Review 5.  Clostridium difficile in long-term-care facilities for the elderly.

Authors:  Andrew E Simor; Suzanne F Bradley; Larry J Strausbaugh; Kent Crossley; Lindsay E Nicolle
Journal:  Infect Control Hosp Epidemiol       Date:  2002-11       Impact factor: 3.254

6.  Recommendations for surveillance of Clostridium difficile-associated disease.

Authors:  L Clifford McDonald; Bruno Coignard; Erik Dubberke; Xiaoyan Song; Teresa Horan; Preeta K Kutty
Journal:  Infect Control Hosp Epidemiol       Date:  2007-01-25       Impact factor: 3.254

7.  Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005.

Authors:  S Paltansing; R J van den Berg; R A Guseinova; C E Visser; E R van der Vorm; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2007-11       Impact factor: 8.067

8.  Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease.

Authors:  Erik R Dubberke; Kimberly A Reske; Margaret A Olsen; Kathleen M McMullen; Jennie L Mayfield; L Clifford McDonald; Victoria J Fraser
Journal:  Arch Intern Med       Date:  2007-05-28

9.  Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors.

Authors:  Erik R Dubberke; Kimberly A Reske; Yan Yan; Margaret A Olsen; L Clifford McDonald; Victoria J Fraser
Journal:  Clin Infect Dis       Date:  2007-12-15       Impact factor: 9.079

10.  Assessment of Clostridium difficile-associated disease surveillance definitions, North Carolina, 2005.

Authors:  Preeta K Kutty; Stephen R Benoit; Christopher W Woods; Arlene C Sena; Susanna Naggie; Joyce Frederick; John Engemann; Sharon Evans; Brian C Pien; Shailendra N Banerjee; Jeffery Engel; L Clifford McDonald
Journal:  Infect Control Hosp Epidemiol       Date:  2008-03       Impact factor: 3.254

View more
  8 in total

1.  Community-associated Clostridium difficile infection: experience of a veteran affairs medical center in southeastern USA.

Authors:  S Naggie; J Frederick; B C Pien; B A Miller; D T Provenzale; K C Goldberg; C W Woods
Journal:  Infection       Date:  2010-05-08       Impact factor: 3.553

Review 2.  The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge.

Authors:  E R Dubberke; D B Haslam; C Lanzas; L D Bobo; C-A D Burnham; Y T Gröhn; P I Tarr
Journal:  Zoonoses Public Health       Date:  2010-09-24       Impact factor: 2.702

3.  Epidemiological model for Clostridium difficile transmission in healthcare settings.

Authors:  C Lanzas; E R Dubberke; Z Lu; K A Reske; Y T Gröhn
Journal:  Infect Control Hosp Epidemiol       Date:  2011-06       Impact factor: 3.254

4.  Frequent hospital readmissions for Clostridium difficile infection and the impact on estimates of hospital-associated C. difficile burden.

Authors:  Courtney R Murphy; Taliser R Avery; Erik R Dubberke; Susan S Huang
Journal:  Infect Control Hosp Epidemiol       Date:  2011-11-11       Impact factor: 3.254

5.  Multicenter study of the impact of community-onset Clostridium difficile infection on surveillance for C. difficile infection.

Authors:  Erik R Dubberke; Anne M Butler; Bala Hota; Yosef M Khan; Julie E Mangino; Jeanmarie Mayer; Kyle J Popovich; Kurt B Stevenson; Deborah S Yokoe; L Clifford McDonald; John Jernigan; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2009-06       Impact factor: 3.254

6.  The magnitude and duration of Clostridium difficile infection risk associated with antibiotic therapy: a hospital cohort study.

Authors:  Kevin A Brown; David N Fisman; Rahim Moineddin; Nick Daneman
Journal:  PLoS One       Date:  2014-08-26       Impact factor: 3.240

7.  Conformational analysis of Clostridium difficile toxin B and its implications for substrate recognition.

Authors:  Rebecca Swett; G Andrés Cisneros; Andrew L Feig
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

8.  Global burden of Clostridium difficile infections: a systematic review and meta-analysis.

Authors:  Evelyn Balsells; Ting Shi; Callum Leese; Iona Lyell; John Burrows; Camilla Wiuff; Harry Campbell; Moe H Kyaw; Harish Nair
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.